This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Intraocular hypertension

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • the normal range for intraocular pressure (IOP) is 10-21mmHg
    • it has a diurnal variation with the highest value seen in the morning (1)

  • ocular hypertension usually refers to any situation in which the IOP is higher than normal. Ocular hypertension is an eye pressure of greater than 21 mm Hg
    • ocular hypertension is commonly defined as a condition with the following criteria:
      • IOP of greater than 21 mm Hg measured in one or both eyes on 2 or more occasions
      • optic nerve appears normal
      • no signs of glaucoma are evident on visual field testing, which is a test to assess your peripheral (or side) vision
      • gonioscopically open angles
    • ocular hypertension in fact has been recognized as the most important risk factor for the development of primary open-angle glaucoma (POAG)
    • 2 per cent of adults have a pressure over 21mmHg with no evidence of glaucoma
      • lowering IOP below 24mmHg will prevent five-year conversion to glaucoma in this group, but the the number of people needed to treat in order to prevent one case of POAG is 15 (1)

  • if glaucomatous damage is present then withholding IOP-lowering treatment results in progressive retinal ganglion cell damage when compared with treated controls

  • progression with IOPs under 30mmHg may take several years; however if there is an IOP higher than 40mmHg then this will result rapid cupping of the disc and loss of visual field
    • a high IOP may also be associated with retinovascular occlusion and sudden loss of sight

  • treatment of intraocular hypertension (2)
    • more recent evidence regarding the possible treatment of intraocular hypertension comes from a study of more than 1,800 patients
    • the European Glaucoma Prevention study investigated the use of dorzolamide versus placebo in patients with intraocular hypertension
      • dorzolamide reduced IOP by 15% to 22% throughout the 5 years of the trial
      • however, the EGPS failed to detect a statistically significant difference between medical therapy and placebo in reducing the incidence of POAG among a large population of OHT patients at moderate risk for developing POAG, because placebo also significantly and consistently lowered IOP
    • knowledge of corneal thickness is no longer needed to decide whether or not to treat OHT and a single threshold of 24 mmHg is now recommended for both onward referral and treatment (4)


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page